Index
Index

Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) (U.S.), 76
National Institute on Drug Abuse (NIDA), 93
National Institute of Mental Health (NIMH), 93
Office of Science, 76
research on the menopause, 93-94
Amenorrhea, 18
American College of Obstetrics and Gynecology, guidance on hormone therapy, 46
American College of Physicians, guidance on hormone therapy, 46
Animal models for research, 88
Arteriosclerosis Research Center, 88
Baltimore Longitudinal Study of Aging (BLSA), 76
Bellergal, 47
Beta-blockers, 47
Bilateral oophorectomy
and breast cancer, 40, 82
as cancer preventative, 20
and cardiovascular disease, 20, 26, 27,40, 77
and estrogen use, 49
and hysterectomy, 20, 22
indications for, 21
and menopausal symptoms, 19
and mortality, 78
and osteoporosis, 20,40, 85
research needs, 85-86
Bioequivalence, for estrogen, 67
Biofeedback, for menopausal symptoms, 48
Bowman Gray School of Medicine, 88
Breast cancer
estrogen, role in, 4,41-43,79-80,86
mortality rates for, 24
research needs, 86
risks for, 79-80
and Tamoxifen, 42
California, hormone prescribing practices in, 69
Cardiovascular disease
and bilateral oophorectomy, 20, 26, 27
and cholesterol, 26, 27,77-79
and estrogen, 4,5,24, 3940,76-77
and hysterectomy, 20
and lipid profiles, 77-79
and menopause, 26
morbidity and disability from, 26
mortality rates for, 24, 26, 27
and progestin, 5
research, in women, 26
and research needs as related to the menopause, 87-89
risk factors for, 40, 80
treatment of, 26
Catapress transdermal patch, 47
Change of life; see Menopause
Cholesterol, high-density lipoprotein (HDL)
and cardiovascular disease, 26, 27
effects of estrogen on, 77-81, 87-89
CIBA, 54,63,71
Climacteric, definition of, 3,4
Combined hormone therapy
administration of, 36-38,70
alternatives to, 46-48, 106
and calcium intake, 39
compliance, 50
definition of, 5n.2
effects on weight gain, 90
FDA advice on, 66, 106
prescribing criterion for, 5
prescribing practices for, 4849,66-70
prevalence of use of, 48-50
professional guidelines for use of, 46
and progestin, 5
refining risks and benefits of, 103-104
side effects of, 37
user of, 49
Comparative Medicine Clinical Research Center, 88
Curetab, 71

Demographics
of menopausal women, 3
Depression, menopausal, 22-23,28,35
Diethylstilbestrol (DES), 92,95
Drug Efficacy Study Implementation (DESI) program, 63
Dyspareunia, 19
Dysuria, 19

Education, need for concerning the menopause and hormone therapy, 106
Endometrial cancer, 64
and estrogen therapy, 4,36,38,40-41,64
and progestin, 5,36-37

Epidemiology
and menopause research, 81-84
and selection bias, 82-83
Estraderm
approved use for, 64, 106
marketing of, 71
Estradiol
ovarian secretion of, 24
receptors for, 22
Estratab, 71
Estratest, 71

Estrogen
and bone loss, 24
and breast cancer, 4
and cardiovascular disease, 24, 27
and endometrial cancer, 4
and hypertriglyceridemia, 27
and low-density lipoprotein cholesterol, 27
production of, 3, 18
protective effects of, 27
receptors for, 24

-123-
tissues affected by, 17,36
and vaginal dryness, 22
and very low density lipoprotein, 27
Estrogen replacement therapy (ERT); see Estrogen therapy
Estrogen Therapy (ET)
alternatives to, 46-48
approved use for, 64
bioequivalence for, 67
and breast cancer, 4,41-43,79-80, 83, 86
cardioprotective effect of, 35-36,3940,65,77-81, 87-89
and compliance, 50
contraindications to use, 36, 65
drug labeling for, 63-65, 105-106
and endometrial cancer, 4, 36, 38,40-41
and hepato(biliary disease, 43
and hot flashes, 4, 35
and lipid profiles, 35,37,3940,77-79, 87
marketing of, 70-71
and menopausal symptoms, 4, 35
opposed vs. unopposed, 4
and overall mortality, 39,78
prescribing practices for, 4849,66-70
prescriptions of, 67-70
and prevention of bone loss, 38-39,79, 89-90
and renal function, 90
routes of administration for, 36
sales figures for, 63
and triglyceride levels, 35,79
and weight gain, 90
Exercise and menopause, 39,48,91
Follicle-stimulating hormone (FSH), in reproductive cycle, 17, 18
Food and Drug Administration (U. S.)
Division of Epidemiology and Surveillance, 68
Fertility and Maternal Health Drugs Advisory Committee,
64-65,66
Generic Drugs Advisory Committee, 67
guidance regarding generic estrogens, 66
guidance regarding osteoporosis, 53
and women’s health issues, 5
Food, Drug, and Cosmetic Act, 63
Framingham Study, 76-77
General Accounting Office (U.S.), 75
Generic estrogens, 66
Ginseng, 48
Glucose metabolism and the menopause, 86-87
effects of progestin on, 87
Goldman, L., 105
Gonadotropin-releasing hormone (GnRH), in reproductive
cycle, 18
Healthy user effect, 82
Healthy Women Study, 77-78,83
Herbal treatments, 47-48
Hormone replacement therapy (HRT); see Combined hormone
therapy
Hormone therapy
definition of, 4n.2
weighing risks and benefits of, 5,49-50, 105
Hot flashes
incidence of, 18
treatment of, 4,64-66
vasomotor symptoms of, 19
Hypermenorrhea, 18
Hypertension, 27
Hypopomenorrhea, 18
Hysterectomy
age at, 21-22, 22
and bilateral oophorectomy, 20, 22
and bone loss, 20, 85
and breast cancer risk, 82
and cardiovascular disease, 20, 77
indications for, 21, 22
and mortality, 78
prevalence of, 19-20,20,21
and psychiatric symptoms, 23
research needs on, 85-86
IMS, America, Ltd., 67
International Consensus Conference on progestin use, 46
International Menopause Society, 51
Involuntary melancholia see Depression, menopausal
Japan, the menopause in, 111-112
Leisure World Study, 78
Lipids
effects of estrogens on, 77-81, 87-89
Lipid Research Clinic Mortality Followup Study, 39,78
Lipid Research Clinic Prevalence Study, 78
Los Angeles County Obstetrics and Gynecology Society, 69
Luteinizing hormone (LH), in reproductive cycle, 18
Massachusetts Women’s Health Study, Part 2, 13,23,48,
49,79,83
Menopause
age at, 3, 17
attitudes toward, 11, 13, 14-15, 16, 23
biolgy of, 15-17,22
and cholesterol levels, 26-27
clinics, 50-52
and cultural factors, 13
definition of, 3,4, 15, 101
and educational materials, 55
effects of smoking on, 77
ethnicity and, 92
factors affecting onset of, 77
historical medical perspectives on, 11, 12-13
hormone levels in, 18
as “medical” condition, 14
mood and behavioral changes in, 22-23
myths regarding, 14
nutritional requirements and, 90
patient and professional education regarding, 52
and psychiatric syndromes, 22
relationship with diseases of aging, 101-102
research needs, 11, 15, 82, 84-91, 102
and roles of women, 11, 14-15, 16
and sexuality, 23
and smoking, 17-18
symptomatology of, 11, 15, 18-19
timing of, 17
Menopause, surgical; see Hysterectomy; Bilateral
oophorectomy
Menorrhagia, 18
Menstruation, study of, 81
Metrorraghia, 18
National Cancer Institute, 42,94
National Center for Nursing Research, 94
National Center for Research Resources, 94
National Disease and Therapeutic Index, 67
National Heart, Lung, and Blood Institute, 42,76,77,78,80,94
National Institute for Dental Research, 94
National Institute on Aging, 76,79,94
National Institute of Arthritis and Musculoskeletal and Skin Diseases, 80,94
National Institute of Child Health and Human Development, 80,94
National Institute of Diabetes and Digestive and Kidney Diseases, 80,94
National Institute of Environmental Health Sciences, 81
National Institutes of Health
  Computer Retrieval of Information on Scientific Projects (CRISP), 92
  Office of Research on Women’s Health, 75-76
  research on menopause, 92-94
  research on women’s health, 5, 6,75
National Osteoporosis Foundations, 42
National Prescription Audit, 67
National Surgical Adjuvant Breast and Bowel Project, 42
Nurses’ Health Study, 5,40,42,79-80,83
Oligomenorrhea, 18
Oral contraceptives
  and postmenopausal hormone use, 102
  risks of use of, 39, 80
Osteoporosis
  and age, as factor in etiology of, 24
  and bilateral oophorectomy, 20
  and bone mass, 25-26
  definition of, 24
  and fractures, 24-25
  in hysterectomized women, 24
  incidence of, 24, 25
  major sites of, 24
  and ovarian hormones, 4, 24, 25
  research needs, 89-90
  risk factors for, 26,40, 90
Ovary, research needs on, 85-86
Pennsylvania State University, 81
Perimenopause
  attitudes toward, 23
  definition of, 3,4, 101
  symptomatology of, 17, 27
Pharmacology, and hormone therapy, 91
Physician’s Desk Reference, 64,65,66
Physician’s Health Study, 84
PMB-200, 64
PMB-400, 64
Postmenopausal Estrogen Progestin Intervention (PEPI) Trial, 69,80-81,83,84,87,92, 103
Premarin
  approved use of, 63-65
  bioequivalence for, 67
  cost of, 106
  marketing of, 54,70
  prescriptions of, 68
  sales of, 63, 106
  use in research participants, 77, 80, 87
Premature ovarian failure, definition of, 17
Premenstrual syndrome (PMS), as psychiatric syndrome, 22
Progesterone
  and bone mass, 25
  receptors for, 22
  in reproductive cycle, 18
Progestins
  alternatives to, 46-47
  approved use of, 65-66
  and breast cancer, 43
  and cardiovascular disease, 5, 37, 77, 87
  and combined hormone therapy, 5, 36-38
  and compliance, 50
  contraindications of, 66, 70
  and endometrial cancer, 5, 36
  and glucose metabolism, 87
  and hot flashes, 37,46
  labeled indications for, 65-66
  marketing of, 70
  prescribing practices for, 68-70
  side effects of, 37
Provera, 63,80,87
Public Health Service (U.S.)
  agenda for women’s health, 75
  Healthy People 2000,94
  investment in menopausal and related research, 92-94
  Task Force on Women’s Health Issues, 73
Randomized trials
  of estrogen, 81-82,83
  need for, 102-103
Reid-Rowell, 71
Research
  estrogen use, 77-81
  Federal investment in, 92-94
  gender-specific perspective in, need for, 3
  menopause, 11, 15,81-92
  methodologic considerations in, 81-84
  needs, 84-91
  women’s health, 75
Risk perception, 49-50, 104-105
Smoking, and menopause, 17-18
Symptoms, menopausal, and bilateral oophorectomy, 19
Tamoxifen, 42
Tosteson, A.N.A., 105
Tremin Trust Research Program on Women’s Health, 81
Tubal ligation, 86
United States Pharmacopoeia 67
University of California, San Diego, 54
University of Minnesota, 81
University of Utah, 81
Upjohn, 63
Urinary stress incontinence, 19
Vaginal atrophy, 18, 19
Veralipride, 47
Very low density lipoprotein (VLDL), and estrogen, 27
Vitamins, 47
Waist-to-hip ratio, 76
Women’s health
  congressional interest in, 5-6
  legislation, in 102nd Congress, 6

Women’s Health Initiative Trial, 84
World Health Organization, 115
Wyeth-Ayerst, 53, 63, 65, 66, 71